Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Department of Neurology, University Hospital Köln, Köln, Germany; University of Düsseldorf, Medical Faculty, Department of Neurology, Düsseldorf, Germany.
J Neuroimmunol. 2019 Jan 15;326:19-27. doi: 10.1016/j.jneuroim.2018.11.002. Epub 2018 Nov 7.
Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.
两种经过验证的检测方法，桥接 ELISA 和基于荧光素酶的生物测定法，用于检测多发性硬化症患者针对干扰素-β (IFN-β) 的抗药物抗体 (ADA)。对参加为期 18 个月的前瞻性研究的患者的血清样本进行了测试。与 ELISA 相反，当测试 IFN-β 特异性兔多克隆和人单克隆抗体时，生物测定法对检测患者血清中的 IFN-β ADA 更敏感。对于临床样本，在使用多层次方法之前，应评估 ELISA 方法的选择。报告了一个滴度阈值值，可作为持续阳性中和 ADA 的预测因子。
